Based on wide-ranging industry discussions, the New York Times ranked BioNet 5th/10 companies globally capable of mRNA manufacture based on suitable production facilities, the availability of skilled workers, the history of drug regulation and certification for drug export, and other political and economic factors that affect research and trade.
BioNet is producing the Ph 2/3 mRNA vaccine developed by Professor Kiat of Chulalongkorn University and Professor Drew Weissman of the University of Pennsylvania. It also produces Covigen, a DNA Covid vaccine developed with Technovalia and Sydney University, currently in Phase 1 trials in Australia.